BDBM318868 N-(3-(2-((4-(4-methylpiperazin-1-yl)phenyl)amino)quinazolin-8-yl)phenyl)acrylamide::US10172868, Compound C021::US10653701, Compound C021::US11304957, Compound C021

SMILES CN1CCN(CC1)c1ccc(Nc2ncc3cccc(-c4cccc(NC(=O)C=C)c4)c3n2)cc1

InChI Key InChIKey=JRQMQSHULVFCLG-UHFFFAOYSA-N

Data  21 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 21 hits for monomerid = 318868   

TargetFibroblast growth factor receptor 1(Human)
Neupharma

US Patent
LigandPNGBDBM318868(US10172868, Compound C021 | N-(3-(2-((4-(4-methylp...)
Affinity DataIC50: 100nMAssay Description:(i) Peptide/Kinase Mixtures for measurement of EGFR (ErbB1):The 2×EGFR (ErbB1)/Tyr 04 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/31/2021
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK3(Human)
Neupharma

US Patent
LigandPNGBDBM318868(US10172868, Compound C021 | N-(3-(2-((4-(4-methylp...)
Affinity DataIC50: 100nMAssay Description:JAK3: The 2×JAK3/Tyr 06 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μL Kinase Reaction consis...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/31/2022
Entry Details
Go to US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Neupharma

US Patent
LigandPNGBDBM318868(US10172868, Compound C021 | N-(3-(2-((4-(4-methylp...)
Affinity DataIC50: 100nMAssay Description:KDR: The 2×KDR (VEGFR2)/Tyr 01 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μL Kinase Reaction...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/31/2022
Entry Details
Go to US Patent

TargetFibroblast growth factor receptor 2(Human)
Neupharma

US Patent
LigandPNGBDBM318868(US10172868, Compound C021 | N-(3-(2-((4-(4-methylp...)
Affinity DataIC50: 100nMAssay Description:FGFR2: The 2×FGFR2/Tyr 04 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 4 mM MnCl2, 1 mM EGTA, 2 mM DTT. The final 10 μ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/31/2022
Entry Details
Go to US Patent

TargetFibroblast growth factor receptor 1(Human)
Neupharma

US Patent
LigandPNGBDBM318868(US10172868, Compound C021 | N-(3-(2-((4-(4-methylp...)
Affinity DataIC50: 100nMAssay Description:FGFR1: The 2×FGFR1/Tyr 04 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 4 mM MnCl2, 1 mM EGTA, 2 mM DTT. The final 10 μ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/31/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK(Human)
Neupharma

US Patent
LigandPNGBDBM318868(US10172868, Compound C021 | N-(3-(2-((4-(4-methylp...)
Affinity DataIC50: 100nMAssay Description:BTK: The 2×BTK/Tyr 01 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μL Kinase Reaction consists...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/31/2022
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor [T790M,L858R](Human)
Neupharma

US Patent
LigandPNGBDBM318868(US10172868, Compound C021 | N-(3-(2-((4-(4-methylp...)
Affinity DataIC50: 100nMAssay Description:EGFR (T790M)(L858R):The 2×EGFR (ErbB1) T790M L858R/Tyr 04 mixture is prepared in 50 mM HEPES pH 6.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 0.02% NaN...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/31/2022
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor(Human)
Neupharma

US Patent
LigandPNGBDBM318868(US10172868, Compound C021 | N-(3-(2-((4-(4-methylp...)
Affinity DataIC50: 100nMAssay Description:EGFR: The 2×EGFR (ErbB1)/Tyr 04 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 4 mM MnCl2, 1 mM EGTA, 2 mM DTT. The final 10 ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/31/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK3(Human)
Neupharma

US Patent
LigandPNGBDBM318868(US10172868, Compound C021 | N-(3-(2-((4-(4-methylp...)
Affinity DataIC50: 100nMAssay Description:(i) Peptide/Kinase Mixtures for measurement of EGFR (ErbB1):The 2×EGFR (ErbB1)/Tyr 04 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/31/2021
Entry Details
Go to US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Neupharma

US Patent
LigandPNGBDBM318868(US10172868, Compound C021 | N-(3-(2-((4-(4-methylp...)
Affinity DataIC50: 100nMAssay Description:(i) Peptide/Kinase Mixtures for measurement of EGFR (ErbB1):The 2×EGFR (ErbB1)/Tyr 04 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/31/2021
Entry Details
Go to US Patent

TargetFibroblast growth factor receptor 2(Human)
Neupharma

US Patent
LigandPNGBDBM318868(US10172868, Compound C021 | N-(3-(2-((4-(4-methylp...)
Affinity DataIC50: 100nMAssay Description:(i) Peptide/Kinase Mixtures for measurement of EGFR (ErbB1):The 2×EGFR (ErbB1)/Tyr 04 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/31/2021
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor(Human)
Neupharma

US Patent
LigandPNGBDBM318868(US10172868, Compound C021 | N-(3-(2-((4-(4-methylp...)
Affinity DataIC50: 100nMAssay Description:The compound of Formula I binds to a kinase selected from the group consisting of EGFR, EGFR L858R, EGFR T790M, EGFR del E746-A750, or EGFR L858R/T79...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/15/2019
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK(Human)
Neupharma

US Patent
LigandPNGBDBM318868(US10172868, Compound C021 | N-(3-(2-((4-(4-methylp...)
Affinity DataIC50: 100nMAssay Description:(i) Peptide/Kinase Mixtures for measurement of EGFR (ErbB1):The 2×EGFR (ErbB1)/Tyr 04 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/31/2021
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor [T790M,L858R](Human)
Neupharma

US Patent
LigandPNGBDBM318868(US10172868, Compound C021 | N-(3-(2-((4-(4-methylp...)
Affinity DataIC50: 100nMAssay Description:(i) Peptide/Kinase Mixtures for measurement of EGFR (ErbB1):The 2×EGFR (ErbB1)/Tyr 04 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/31/2021
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor(Human)
Neupharma

US Patent
LigandPNGBDBM318868(US10172868, Compound C021 | N-(3-(2-((4-(4-methylp...)
Affinity DataIC50: 100nMAssay Description:(i) Peptide/Kinase Mixtures for measurement of EGFR (ErbB1):The 2×EGFR (ErbB1)/Tyr 04 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/31/2021
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK3(Human)
Neupharma

US Patent
LigandPNGBDBM318868(US10172868, Compound C021 | N-(3-(2-((4-(4-methylp...)
Affinity DataIC50: 100nMAssay Description:The compound of Formula I binds to a kinase selected from the group consisting of EGFR, EGFR L858R, EGFR T790M, EGFR del E746-A750, or EGFR L858R/T79...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/15/2019
Entry Details
Go to US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Neupharma

US Patent
LigandPNGBDBM318868(US10172868, Compound C021 | N-(3-(2-((4-(4-methylp...)
Affinity DataIC50: 100nMAssay Description:The compound of Formula I binds to a kinase selected from the group consisting of EGFR, EGFR L858R, EGFR T790M, EGFR del E746-A750, or EGFR L858R/T79...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/15/2019
Entry Details
Go to US Patent

TargetFibroblast growth factor receptor 2(Human)
Neupharma

US Patent
LigandPNGBDBM318868(US10172868, Compound C021 | N-(3-(2-((4-(4-methylp...)
Affinity DataIC50: 100nMAssay Description:The compound of Formula I binds to a kinase selected from the group consisting of EGFR, EGFR L858R, EGFR T790M, EGFR del E746-A750, or EGFR L858R/T79...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/15/2019
Entry Details
Go to US Patent

TargetFibroblast growth factor receptor 1(Human)
Neupharma

US Patent
LigandPNGBDBM318868(US10172868, Compound C021 | N-(3-(2-((4-(4-methylp...)
Affinity DataIC50: 100nMAssay Description:The compound of Formula I binds to a kinase selected from the group consisting of EGFR, EGFR L858R, EGFR T790M, EGFR del E746-A750, or EGFR L858R/T79...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/15/2019
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK(Human)
Neupharma

US Patent
LigandPNGBDBM318868(US10172868, Compound C021 | N-(3-(2-((4-(4-methylp...)
Affinity DataIC50: 100nMAssay Description:The compound of Formula I binds to a kinase selected from the group consisting of EGFR, EGFR L858R, EGFR T790M, EGFR del E746-A750, or EGFR L858R/T79...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/15/2019
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor [T790M,L858R](Human)
Neupharma

US Patent
LigandPNGBDBM318868(US10172868, Compound C021 | N-(3-(2-((4-(4-methylp...)
Affinity DataIC50: 100nMAssay Description:The compound of Formula I binds to a kinase selected from the group consisting of EGFR, EGFR L858R, EGFR T790M, EGFR del E746-A750, or EGFR L858R/T79...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/15/2019
Entry Details
Go to US Patent